Latest News
All the latest company news from Oxford Vacmedix
Oxford Vacmedix licenses OVM-200 to Dx&Vx
Oxford Vacmedix licences cancer vaccine OVM-200 to leading shareholder Dx&Vx, for development in South Korea, China, and India. Oxford, UK – 13th December 2024 Press release – OVM-200 licenced to Dx&Vx Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer, announced today the finalisation of a licensing deal for its lead cancer […]
UK charity Prostate Cancer Research invests in Oxford Vacmedix Series B
Support from leading Prostate cancer charity for the clinical development of OVM-200. Oxford, UK – 27th November 2024 Press Release – Prostate Cancer Research invests in Oxford Vacmedix Series B Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer, announced today Series B investment from Proven Connect, the translational arm of the charity […]
Oxford Vacmedix announces lead investment for Series B fund
Lead investment of $3.0 million in Oxford Vacmedix Series B from existing investors. Oxford, UK – 6th November 2024 Press Release – Oxford Vacmedix announces lead investment for Series B fund Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer announced today the lead investment in its Series B fund of $3.0m […]
Oxford Vacmedix announces grant from Innovate UK for OVM-200 clinical trial
Prostate Cancer Research’s Proven Connect supports grant application and facilitates additional funding for the clinical development of OVM’s lead cancer vaccine, OVM-200. Oxford – 31st July 2024 Press Release – Oxford Vacmedix announces grant from Innovate UK for OVM-200 clinical trial Oxford Vacmedix (OVM), developing therapeutic cancer vaccines, announced today the grant of a prestigious […]
Oxford Vacmedix wins 1st prize in 2024 Talent, Innovation and Entrepreurship Competition
Oxford Vacmedix has won the 1st prize in the China Overseas Talents Competition (UK Division) The UK section of the competition was held in London on 14th June 2024 and Oxford Vacmedix won 1st prize from a strong field of 25 competitors. The international judges were impressed by the company’s groundbreaking ROP (Recombinant Overlapping […]
Regulatory approval of novel TB diagnostic in China granted to OVM licensee CBI
Regulatory approval of novel TB diagnostic in China granted to Oxford Vacmedix licensee Changzhou Biotech First regulatory approval worldwide for any application of the Recombinant Overlapping Peptide (ROP) technology Oxford, UK – 25th April 2024 Press Release – Regulatory approval granted for novel TB diagnostic Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to […]
Oxford Vacmedix licences AMR diagnostic to Changzhou Biotech
Oxford Vacmedix licences its novel diagnostic test for Anti Microbial Resistance to Changzhou Biotech for Greater China Oxford, UK – 11th April 2024 Press Release – OVM licences AMR diagnostic to CBI Oxford Vacmedix (OVM), the clinical stage company developing therapeutic cancer vaccines, announced today the grant of a licence for its novel diagnostic test […]
New opportunity for Oxford Vacmedix future clinical development through sale of Head of Clinical Operations, Mark Thomas’ company Clinicology Ltd.
FGK Clinical Research GmbH, announces the successful acquisition of Clinicology Ltd. This strategic move marks a significant milestone for both companies and benefits OVM Oxford, UK – 4th March 2024 Press Release – Sale of Clinicology Ltd. Oxford Vacmedix (OVM), the clinical stage company developing therapeutic cancer vaccines, announced today that Clinicology Ltd, the contract […]
Oxford Vacmedix team support new University of Oxford educational initiative
The team at Oxford Vacmedix contribute to the design and the delivery of a novel MSc course in Applied Cancer Science being run by the Department of Oncology at the University of Oxford Oxford, UK – 26th February 2024 Press Release – Oxford Vacmedix support new University of Oxford educational initiative Oxford Vacmedix (OVM), the […]
Oxford Vacmedix announces major milestone in clinical development of OVM-200
OVM-200 Drug Product, manufactured to Good Manufacturing Process (GMP), has been certified stable three years post manufacture – a major milestone for OVM’s lead cancer vaccine, OVM-200 Oxford, UK – 31st January 2024 Press Release – OVM-200 major milestone three year stabilty Oxford Vacmedix (OVM), the clinical stage company developing therapeutic cancer vaccines, announced today […]
Licensing deal with Dx&Vx for OVM-200 in South Korea and China
Ongoing discussions at an advanced stage with leading shareholder DxVx, to license OVM-200 for South Korea and for China. Oxford, UK – 28th November 2023 Press Release – Licensing deal with Dx&Vx for OVM-200 in South Korea and China Oxford Vacmedix (OVM), the UK-based biopharma company developing vaccines to treat cancer announced today ongoing licensing […]
New publication highlights importance of survivin as target and potential for combination use to treat cancer
A new publication in Advanced Therapeutics comprehensively reviews the rationale and preclinical results for OVM-200 both alone and in combination. Oxford, UK – 10th October 2023 Press Release – Importance of Survivin as a target and potential for combination use to treat cancer Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of […]
Oxford Vacmedix feature in ‘Advancing Immunology’
Oxford Vacmedix to feature in ITN Business’ programme ‘Advancing Immunology’ – exploring the use of new technology to develop vaccines to treat cancer Oxford, UK – 26th May 2023 ITN Business present Oxford Vacmedix in a new series on ‘Advancing Immunology’. The programme explores how cancer therapeutic vaccines are being trialled and could reduce the […]
Oxford Vacmedix announces major manufacturing milestone for OVM-200
OVM-200 Drug Product, manufactured to Good Manufacturing Process (GMP), has been certified stable two years post manufacture – a major milestone for OVM’s lead cancer vaccine development Oxford, UK – 12th May 2023 Press Release – Oxford Vacmedix announces major manufacturing milestone for OVM-200 Oxford Vacmedix (OVM), the UK-based biopharma company developing therapeutic cancer vaccines, […]
Oxford Vacmedix sponsors MRC i-Case studentship at University of Oxford
New appointment In Professor Shisong Jiang’s research group in the Department of Oncology brings further expertise to research applications for Recombinant Overlapping Peptides (ROPs) Oxford, UK – 5th April 2023 Press Release – Oxford Vacmedix sponsors MRC i-Case studentship at University of Oxford Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of […]
Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200
The initial part of a Phase I trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been completed – the first clinical trial of a cancer vaccine using novel ROP technology. Oxford, UK – 29th March 2023 Press Release – Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200 […]
OVM-200 Phase 1 Clinical Trial featured on TV
The OVM-200 Phase 1 Clinical Trial at The Christie in Manchester was featured on ITV’s Granada News on Wednesday 7th September 2022. It is a first-in-class of ROP cancer vaccine in human clinical trial. ROP therapeutic vaccines will provide additional options for the treatment of cancer patients. Professor Shisong Jiang, Chief Scientific Officer and Founder […]
Oxford Vacmedix announces filing of new patent for Anti-Microbial Resistance diagnostic test
New patent for a novel diagnostic test to detect anti-microbial resistance filed, after successful completion of development and initial testing Oxford, 27th July 2022 Press Release – Oxford Vacmedix announces filing of new patent for Anti-Microbial Resistance diagnostic test Oxford Vacmedix (OVM), the UK clinical stage biopharma company, focused on the development of a new […]
In Vitro and In Vivo Antigen Presentation and Diagnosis Development of Recombinant Overlapping Peptides Corresponding to Mtb ESAT-6/CFP-10
The following publication describes a study developing the ROP-TB antigen for both in vitro IGRA-based TB diagnosis, as well as the in vivo skin test for TB diagnosis in both humans and cattle. The advantages of the ROP-TB diagnosis are firstly distinguishing Mtb infection from BCG vaccination, and secondly, being suitable for industrial manufacture. Read […]
Oxford Vacmedix announces Innovate UK funding for development of novel T-cell potency assays
Oxford Vacmedix announces Innovate UK funding for development of novel T-cell potency assays. Project with Department of Oncology, University of Oxford and Reading Scientific Services (RSSL) to develop the methodology for T-cell potency assays of vaccines. Oxford, 25th May 2022 Press Release – Innovate UK funding for development of novel T-cell potency assays Oxford Vacmedix […]
Oxford Vacmedix founder Dr Shisong Jiang invited to Buckingham Place
Dr Shisong Jiang recieved an invitation to the annual Royal Garden Party to recognise many years’ service to charity. Oxford, 23rd May 2022 Press Release – Dr Shisong Jiang invited to Buckingham Palace On Wednesday 18 May, the Dr Shisong Jiang, the founder and CSO of Oxford Vacmedix, was invited to Buckingham Palace in London […]
Editorial: Research, Development and Clinical Trials for Peptide-Based Vaccines
From the eradication of smallpox through to the global response to the COVID-19 pandemic, vaccines have been a cornerstone in the fight against infectious diseases in humans and livestock since the 18th century. Although vaccines against COVID-19 are unlikely to eradicate the disease in the way that the smallpox vaccine did, they have proved very […]
HPV-16 E7-Specific Cellular Immune Response
HPV-16 E7-Specific Cellular Immune Response in Women With Cervical Intraepithelial Lesion Contributes to Viral Clearance: A Cross-Sectional and Longitudinal Clinical Study High-risk human papillomavirus (HPV) infection is the cause of almost all cervical cancers. HPV16 is one of the main risk subtypes. Although screening programs have greatly reduced the prevalence of cervical cancer in developed […]
Survivin as a biological biomarker for diagnosis and therapy
Survivin (SVN) is a member of the inhibitor of apoptosis (IAP) protein family that promotes cellular proliferation and inhibits apoptosis. Overexpression of SVN is associated with autoimmune disease, hyperplasia, and tumors and can be used as a biomarker in these diseases. SVN is widely recognized as a tumor-associated antigen (TAA) and has become an important […]
First patient treated with novel Cancer Vaccine
A Phase I trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has started – the first clinical trial of a cancer vaccine using the novel technology. Press Release – Oxford group announces first patient treated with novel cancer vaccine Oxford, 4th November 2021: Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of […]
Mr Chong-Yoon Lim of Hanmi Science appointed as a Director
Appointment brings in-depth expertise of company development and investment and enhanced contacts in Asia to Oxford Vacmedix Press Release – Appointment of Mr Choon-Yoon Lim as Director Oxford 19th October 2021: Oxford Vacmedix (OVM), the UK-based biopharma company focused on the development of cancer vaccines announced today the appointment of Mr. Chong-Yoon Lim as a […]
MHRA approval for Phase 1 trial of lead cancer vaccine OVM-200
Regulatory approval of OVM-200 for Phase 1 signals a significant step for Oxford Vacmedix with the first clinical trial of a cancer vaccine based on the recombinant overlapping peptide platform Oxford 10th August 2021; Oxford Vacmedix, the UK-based biopharma company focused on the development of cancer vaccines announced today that approval for a Phase 1 […]
Beyond Just Peptide Antigens: The complex world of peptide-based cancer vaccines
Therapeutic vaccines may well be the next wave of immunotherapy for cancer treatment. Peptide-based vaccines will play a pivotal role in the field. How is a peptide vaccine designed? What other factors such as adjuvants etc should be considered? Can Immunol oncological agents be synergetic with peptide vaccines? Read the full article: Beyond Just Peptide […]
Mark Thomas appointed as Head of Clinical Operations
Oxford Vacmedix UK Ltd announces the appointment of Mark Thomas as Head of Clinical Operations, bringing in-depth expertise in running clinical trials and in pharmaceutical development to Oxford Vacmedix. Press Release – appointment of Mark Thomas as Head of Clinical Operations Oxford, 14th June 2021: Oxford Vacmedix, the UK-based biopharma company focused on the development […]
Dr Thomas Morris appointed as Chief Medical Officer
Oxford Vacmedix UK Ltd announces the appointment of Dr Thomas Morris as Chief Medical Officer, bringing in-depth expertise in oncology clinical development to the Company. Press Release – Dr Thomas Morris appointed as Chief Medical Officer Oxford, 23rd March 2021: Oxford Vacmedix, the UK-based biopharma company focused on the development of cancer vaccines announced today […]
Oxford Vacmedix and CHAIN Biotech collaborate to develop oral vaccines
Oxford Vacmedix and CHAIN Biotech have signed Heads of Terms for a Collaboration Agreement to develop and commercialise oral vaccines targeting cancer & infectious disease Oxford, UK – 4th January 2020 – FOR IMMEDIATE RELEASE Press Release – OVM CHAIN Collaboration Oxford 4th Jan 2020; Oxford Vacmedix (OVM), the UK based biopharma company, focused on […]
Oxford Vacmedix announces filing of new patent for Covid-19 vaccine and diagnostics
New patent using Recombinant Overlapping Peptide (ROP technology) as novel approach to SARS-Cov-2 pandemic filed, after rapid development and initial testing Oxford, UK – 24th November 2020 – FOR IMMEDIATE RELEASE Press Release-Patent filed for Covid-19 vaccine and diagnostics 24-11-20 Oxford 24th November 2020; Oxford Vacmedix (OVM), the UK based biopharma company, focused on the […]
Oxford Vacmedix founder Dr Shisong Jiang appointed as Senior Industrial Fellow at University of Oxford
Shisong Jiang is appointed to the newly created role of Senior Industrial Fellow in the Department of Oncology at the University of Oxford Oxford, UK – 9th November 2020 – FOR IMMEDIATE RELEASE Download PDF – Press Release-Senior Industrial Fellow 09-11-20 Oxford 9th November 2020; Oxford Vacmedix (OVM), the UK based biopharma company, focused on […]
Oxford Vacmedix announces collaboration to develop vaccine and diagnostic tests for Covid-19
Collaboration with the Nuffield Department of Medicine, University of Oxford will use recombinant overlapping peptide technology to develop a novel vaccine and diagnostic tests for Covid-19 Press Release Covid-19 project 12 May 2020 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focusing on the development of cancer vaccines, announced today that it will use […]
Comparing Pooled Peptides with Intact Protein for Accessing Cross-presentation Pathways for Protective CD8 and CD4 T Cells
Zhang et al – 2009 (view in PDF)
Mouse Model for Pre-Clinical Study of Human Cancer Immunotherapy
Ya Z. et al – 2015 (view in PDF)
WHO guidelines on nonclincial evaluation of vaccines
WHO Guideline – nonclinical_evaluation_vaccines_nov_2003
A Bayesian design for phase I cancer therapeutic vaccine trials
Wang, Rosner and Roden – 2019 (view in PDF)
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial
van Poelgeest e al – 2013 (view in PDF)
ELISpot for measuring human immune responses to vaccines
Slota et al – 2011 (view in PDF)
Vaccine Immunology
Siegrist C-A – 2012
Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation
Rosalia et al – 2013 (view in PDF)
Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class II T cell epitopes by dendritic cells
Rabu C et al, Oncoimmunology 2019 (view in PDF)
T cell responses: naïve to memory and everything in between
Pennock et al – 2013 (view in PDF)
B16 as a Mouse Model for Human Melanoma
Overwijk and Restifo – 2001 (view as PDF)
Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade
Mougel, Terme and Tanchot – 2019 (view in PDF)
Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer
Miyazaki et al – 2011 (view as PDF)
Risk of anaphylaxis after vaccination in children and adults
McNeil et al – 2016 (view as PDF)
Immunization of Mice
Maira-Litran et al – 2017 (view as PDF)
Survivin as a novel target protein for reducing the proliferation of cancer cells (Review)
Li, Hu and Li -2018 (view as PDF)
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
Kenter et al – 2009 (view as PDF)
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials
Johnson et al -2001 (view as PDF)
Overlapping synthetic peptides as vaccines
Jiang et al – 2006 (view as PDF)
Expression and clinical significance of survivin in ovarian cancer: A meta-analysis
He et al – 2018 (view as PDF)
Therapeutic Cancer Vaccines: Past, Present and Future
Guo et al – 2013 (view as PDF)
Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines
Guidance for Industry, Clinical Considerations for Therapeutic Cancer Vaccines (view as PDF)
Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma
Fenstermaker et al – 2016 (view as PDF)
Protective cellular immunity generated by cross-presenting recombinant overlapping peptide proteins
Cai et al -2017 (view as PDF)
Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients
Berinstein et al – 2015 (view as PDF)
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
Ambrosini, Adida and Altieri -1997 (view as PDF)
Cancer vaccine firm Oxford Vacmedix appoints leading global CRO to run Phase 1 trial of OVM-200
Oxford Vacmedix appoints a Global Contract Research Organisation (CRO) to run a Phase 1 trial of immunotherapy cancer vaccine OVM-200 in the UK. Oxford, UK – 24th January 2020 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today that a leading global CRO has been appointed […]
Cancer vaccine firm Oxford Vacmedix announces Innovate UK grant for novel application of ROP technology
Grant will fund joint research by Imperial College, London and Oxford Vacmedix into antimicrobial resistance, in collaboration with the Ditan Hospital in Beijing, China Oxford, UK – 19th December 2019 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focusing on the development of cancer vaccines, announced today the award of an Innovate UK grant […]
Cancer vaccine firm Oxford Vacmedix appoints Eurofins CDMO as Contract Development & Manufacturing Organisation
Oxford Vacmedix appoints Belgium based Eurofins CDMO to carry out the GMP manufacturing of the lead immunotherapy cancer vaccine OVM-200, to support Phase 1 application. Oxford, UK – 22nd November 2019 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today that Eurofins CDMO based in Belgium […]
Oxford Vacmedix announces Research Collaboration with University of Oxford
Grant to fund research into novel applications and development of new cancer vaccines using the recombinant overlapping peptide technology developed by Dr. Shisong Jiang. Oxford, UK – 9th July 2019 Oxford Vacmedix (OVM), the UK based biopharma company, focused on the development of a new generation of cancer vaccines, announced today that research into its […]
Cancer vaccine firm Oxford Vacmedix announces collaboration and Innovate UK grant
CHAIN Biotechnology and University of Oxford have been awarded grant funding to develop live biotherapeutics that support oral delivery of Oxford Vacmedix’s immunotherapy cancer vaccines. Oxford, UK – 2nd July 2019 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today the award of an Innovate UK […]
Cancer vaccine firm Oxford Vacmedix appoints Xpress Biologics as Contract Manufacturing Organisation
Oxford Vacmedix appoints Belgium based Xpress Biologics to carry out the GLP manufacturing of both lead immunotherapy cancer vaccines, to support Phase 1 applications. Oxford, UK – 8th February 2019 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today that Xpress Biologics based in Belgium has […]
Cancer vaccine firm Oxford Vacmedix holds first meeting of Scientific Advisory Council
Leading international experts advise Oxford Vacmedix on development programme Oxford, UK – 31st January 2019 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announces today the first meeting of its Scientific Advisory Council. World-class experts gathered to guide the research and preclinical development programmes of the company […]
Professor Xiao-Ning Xu joins Scientific Advisory Council of Oxford Vacmedix
Appointment brings further expertise in immunology and pharmaceutical development to Oxford Vacmedix Oxford 12th October 2018; Oxford Vacmedix, the UK-based biopharma company focused on the development of cancer vaccines announced today that Professor Xiao-Ning Xu will join the company’s Scientific Advisory Council. Professor Xu is an immunologist who was previously a research leader at the […]
Professor Sir Andrew McMichael joins Scientific Advisory Council of Oxford Vacmedix
World-class immunologist to advise Oxford Vacmedix on development of novel cancer vaccines. Oxford Vacmedix, a UK-based biopharma company focused on the development of cancer vaccines, announced today that Professor Sir Andrew McMichael will join the company’s Scientific Advisory Council. Sir Andrew is an immunologist, Emeritus Professor, former Professor of Molecular Medicine, and previously Director of […]
Cancer vaccine firm Oxford Vacmedix confirms appointment of new Directors
Directors join Oxford Vacmedix from Myongji Hospital Group and Series A investors Cancer ROP in South Korea and Mr Jin from China. Oxford Vacmedix UK Limited (OVM), the UK-‐based biopharma company focused on the development of cancer vaccines, confirmed today the appointment of new Directors to the Board. These new appointments follow the successful Series […]
Cancer vaccine firm Oxford Vacmedix appoints PharmaLegacy as Contract Research Organisation
Oxford Vacmedix appoints Shanghai based PharmaLegacy to carry out the proof of concept work of both lead immunotherapy cancer vaccines, to support Phase 1 applications. Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today that PharmaLegacy of Shanghai, China has been appointed to complete the proof […]
Oxford Vacmedix ROP technology presented at 2018 Myongji International Cancer Symposium
June 2018 – Oxford Vacmedix ROP technology presented at 2018 Myongji International Cancer Symposium View in PDF
Oxford Vacmedix completes Series A financing
Oxford Vacmedix UK Limited (OVM) has completed its Series A financing round of $12.5m (£9m). Oxford Vacmedix UK Limited (OVM), a UK-based biopharma company focused on the development of cancer vaccines, has completed its Series A financing round of $12.5m (£9m) with a consortium of South Korean and Chinese investors, including Cancer ROP, a leading […]
An informative article in advertising feature in Nature Biotechnology Sep 2017
Biopharmadealmakers.nature.com | September 2017; Oxford Vacmedix Ltd.: harnessing the power of immunotherapy to treat and monitor cancer View in PDF
Protective cellular immunity generated by cross-presenting recombinant overlapping peptide proteins
Lili Cai, Jianbo Zhang et al, Oncotarget August 24, 2017 View in PDF
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines
Melief CJ, van der Burg SH. Nat Rev Cancer. 2008 May;8(5):351-60.
Therapeutic Cancer Vaccines
Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH. J Clin Invest. 2015 Sep;125(9):3401-12. View in PDF
Comparing Pooled Peptides with Intact Protein for Accessing Cross-presentation Pathways for Protective CD8 and CD4 T Cells
Zhang, H et al. The Journal of Biological Chemistry, VOL.284,NO.14,pp.9184–9191, April 3,2009 View in PDF
Contact us
If you want to have a quick chat, or leave us some feedback,
you can contact us using any of the methods below
- www.oxfordvacmedix.com
- enquiries@oxfordvacmedix.com
- +44 (0) 1865 784074
- Oxford Vacmedix UK Limited, The Magdalen Centre, The Oxford Science Park, Oxford, OX4 4GA